Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 91, Issue 2, Pages 127-139Publisher
SPRINGER
DOI: 10.1007/s11060-008-9691-5
Keywords
Malignant glioma; Immunotherapy; Dendritic cells; In vivo bioluminescence; Stereomicroscopy; Validation
Categories
Funding
- Olivia Hendrickx Research Fund
- Institute for the Promotion of Innovation through Science and Technology in Flanders
- MoSAIC Excellence
Ask authors/readers for more resources
The value of bioluminescence imaging (BLI) for experimental cancer models has become firmly established. We applied BLI to the GL261 glioma model in the context of dendritic cell (DC) immunotherapy. Initial validation revealed robust linear correlations between in vivo, ex vivo and in vitro luciferase activity measurements. Ex vivo BLI demonstrated midline crossing and leakage of tumor cells. Orthotopically challenged mice followed with BLI showed an initial adaptation phase, after which imaging data correlated linearly with stereologically determined tumor dimensions. Transition from healthy to moribund state corresponded with an increasing in vivo flux but the onset of neurological deficit was clearly delayed compared to the onset of in vivo flux increase. BLI was implemented in prophylactic immunotherapy and imaging data were prognostic for therapy outcome. Three distinct response patterns were detected. Our data underscore the feasibility of in vivo BLI in an experimental immunotherapeutic setting in the GL261 glioma model.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available